BACKGROUND: Congestive heart failure (CHF) is associated with persistent immune activation. Medical therapy has been shown to exert only limited anti-inflammatory effects. Cardiac resynchronization therapy (CRT) reduces morbidity and mortality in a subset of patients with heart failure, but it is not known whether this treatment affects the immune system as well. To test this hypothesis, eight patients with heart failure scheduled for CRT were investigated for immune activation before and 6 months after CRT treatment. METHODS AND RESULTS: After 6 months, all patients had improved in NYHA-class and LVEF, and there was a statistically significant reduction in serum N-terminal pro brain natriuretic peptide (BNP). Furthermore, there was a statistically significant reduction in plasma levels of the chemokines monocyte chemoattractant protein 1 (MCP-1) and interleukin 8 (IL-8) and the cytokine interleukin 6 (IL-6). We observed no changes in the levels of interleukin 1beta (IL-1beta), tumor necrosis factor alpha (TNF-alpha), interleukin 10 (IL-10), or complement activation products. There was a significant correlation between changes in BNP and IL-6 (r = 0.74, P = 0.037). CONCLUSION: Although based upon a limited number of patients, this report indicates that CRT reduces peripheral markers of immune activation in patients with CHF. Further large scale studies are warranted to verify these findings.
BACKGROUND:Congestive heart failure (CHF) is associated with persistent immune activation. Medical therapy has been shown to exert only limited anti-inflammatory effects. Cardiac resynchronization therapy (CRT) reduces morbidity and mortality in a subset of patients with heart failure, but it is not known whether this treatment affects the immune system as well. To test this hypothesis, eight patients with heart failure scheduled for CRT were investigated for immune activation before and 6 months after CRT treatment. METHODS AND RESULTS: After 6 months, all patients had improved in NYHA-class and LVEF, and there was a statistically significant reduction in serum N-terminal pro brain natriuretic peptide (BNP). Furthermore, there was a statistically significant reduction in plasma levels of the chemokines monocyte chemoattractant protein 1 (MCP-1) and interleukin 8 (IL-8) and the cytokine interleukin 6 (IL-6). We observed no changes in the levels of interleukin 1beta (IL-1beta), tumor necrosis factor alpha (TNF-alpha), interleukin 10 (IL-10), or complement activation products. There was a significant correlation between changes in BNP and IL-6 (r = 0.74, P = 0.037). CONCLUSION: Although based upon a limited number of patients, this report indicates that CRT reduces peripheral markers of immune activation in patients with CHF. Further large scale studies are warranted to verify these findings.
Authors: Gábor Széplaki; András Mihály Boros; Szabolcs Szilágyi; István Osztheimer; Zsigmond Jenei; Annamária Kosztin; Klaudia Vivien Nagy; Júlia Karády; Levente Molnár; Tamás Tahin; Endre Zima; László Gellér; Zoltán Prohászka; Béla Merkely Journal: Inflamm Res Date: 2016-08-04 Impact factor: 4.575
Authors: Andrzej Rubaj; Piotr Ruciński; Krzysztof Oleszczak; Michał K Trojnar; Maciej Wójcik; Andrzej Wysokiński; Andrzej Kutarski Journal: Heart Vessels Date: 2012-12-16 Impact factor: 2.037
Authors: Kenneth M Stein; Kenneth A Ellenbogen; Michael R Gold; Bernd Lemke; Ignacio Fernández Lozano; Suneet Mittal; Francis G Spinale; Jennifer E Van Eyk; Alan D Waggoner; Timothy E Meyer Journal: Pacing Clin Electrophysiol Date: 2009-10-10 Impact factor: 1.976